Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemia-Reference-Cited by-同舟云学术

Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemia

Published:2016-12-28 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Villarroel Gonzalez Dagmar¹,Elter Thomas²,Monsef Ina³,Engert Andreas¹,Skoetz Nicole³

Affiliation:

1. University Hospital of Cologne; Department I of Internal Medicine; Kerpener Straße 62 Cologne Germany 50924

2. University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn; Kerpener Str. 62 Cologne Germany 50924

3. University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010124.pub2/epdf/full

Reference43 articles.

1. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia;Bellosillo;Blood,1999

2. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis;Binet;Cancer,1981

3. Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation;Brugiatelli;Haematologica,2006

4. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications;Campo;Blood,2011

5. Chronic lymphocytic leukemia;Chiorazzi;The New England Journal of Medicine,2005